SRTA STRATA CRITICAL MEDICAL INC revenue, earnings and financials
For the quarter ended June 30, 2026, STRATA CRITICAL MEDICAL INC reported revenue of $72.5M (up 60.7% from a year earlier), net income of −$10.5M and diluted EPS of −$0.12; over the last four quarters revenue was $256M and net income $40.2M; for the fiscal year ended December 2025 revenue was $197M, up 34.3% on the year before.
SRTA annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $197M, gross profit $41.1M, operating income −$22.4M, net income $41.3M (margin 21.0%), EPS $0.50
- Fiscal year ended Dec 2024: revenue $147M, gross profit $29.6M, operating income −$22.5M, net income −$27.3M (margin -18.6%), EPS −$0.35
- Fiscal year ended Dec 2023: revenue $225M, gross profit n/a, operating income −$68.1M, net income −$56.1M (margin -24.9%), EPS −$0.76
- Fiscal year ended Dec 2022: revenue $146M, gross profit n/a, operating income −$53.5M, net income −$27.3M (margin -18.7%), EPS −$0.38
- Fiscal year ended Sep 2021: revenue $50.5M, gross profit n/a, operating income −$24.1M, net income −$40.1M (margin -79.3%), EPS −$0.93
SRTA quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $72.5M (up 60.7% year over year), net income −$10.5M, EPS −$0.12
- Quarter ended Mar 31, 2026: revenue $67.4M (up 87.4% year over year), net income $2.15M, EPS $0.03
- Quarter ended Dec 31, 2025 (from the annual report): revenue $66.8M (up 867.3% year over year), net income −$8.83M, EPS −$0.11
- Quarter ended Sep 30, 2025: revenue $49.3M (up 36.7% year over year), net income $57.4M, EPS $0.70
- Quarter ended Jun 30, 2025: revenue $45.1M (down 33.6% year over year), net income −$3.74M, EPS −$0.05
- Quarter ended Mar 31, 2025: revenue $35.9M (down 30.2% year over year), net income −$3.49M, EPS −$0.04
- Quarter ended Dec 31, 2024 (from the annual report): revenue −$8.70M (down 118.3% year over year), net income −$9.79M, EPS −$0.11
- Quarter ended Sep 30, 2024: revenue $36.1M (down 49.5% year over year), net income −$1.95M, EPS −$0.03
- Quarter ended Jun 30, 2024: revenue $67.9M (up 11.4% year over year), net income −$11.3M, EPS −$0.15
- Quarter ended Mar 31, 2024: revenue $51.5M (up 13.8% year over year), net income −$4.23M, EPS −$0.06
- Quarter ended Dec 31, 2023 (from the annual report): revenue $47.5M (up 24.5% year over year), net income −$33.9M, EPS −$0.45
- Quarter ended Sep 30, 2023: revenue $71.4M (up 56.3% year over year), net income $289K, EPS $0.00
- Quarter ended Jun 30, 2023: revenue $61.0M (up 71.2% year over year), net income −$12.2M, EPS −$0.17
- Quarter ended Mar 31, 2023: revenue $45.3M (up 70.0% year over year), net income −$10.2M, EPS −$0.14
- Quarter ended Dec 31, 2022 (from the annual report): revenue $38.1M (up 54.9% year over year), net income −$27.3M, EPS −$0.19
- Quarter ended Sep 30, 2022: revenue $45.7M (up 125.1% year over year), net income −$9.25M, EPS −$0.13
- Quarter ended Jun 30, 2022: revenue $35.6M (up 175.1% year over year), net income $8.41M, EPS $0.10
- Quarter ended Mar 31, 2022: revenue $26.6M (up 187.2% year over year), net income −$11.0M, EPS −$0.16
- Quarter ended Dec 31, 2021: revenue $24.6M (up 208.3% year over year), net income $772K, EPS $0.01
- Quarter ended Sep 30, 2021: revenue $20.3M, net income −$9.18M, EPS −$0.13
SRTA cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$48.9M, share buybacks $0
- Fiscal year ended Dec 2024: operating cash flow −$2.52M, share buybacks $244K
- Fiscal year ended Dec 2023: operating cash flow −$32.3M, share buybacks $0
- Fiscal year ended Dec 2022: operating cash flow −$37.1M, share buybacks n/a
- Fiscal year ended Sep 2021: operating cash flow −$15.6M, share buybacks n/a
SRTA balance sheet
- Jun 30, 2026: cash $16.3M, total assets $333M, total liabilities $53.4M, shareholders' equity $279M
- Mar 31, 2026: cash $58.7M, total assets $328M, total liabilities $41.9M, shareholders' equity $286M
- Dec 31, 2025: cash $31.0M, total assets $325M, total liabilities $46.4M, shareholders' equity $279M
- Sep 30, 2025: cash $22.8M, total assets $335M, total liabilities $52.1M, shareholders' equity $283M
- Jun 30, 2025: cash $58.8M, total assets $258M, total liabilities $34.8M, shareholders' equity $223M
- Mar 31, 2025: cash $34.8M, total assets $251M, total liabilities $30.8M, shareholders' equity $220M
- Dec 31, 2024: cash $18.4M, total assets $257M, total liabilities $34.7M, shareholders' equity $222M
- Sep 30, 2024: cash $20.0M, total assets $283M, total liabilities $49.4M, shareholders' equity $233M
What is SRTA's revenue?
STRATA CRITICAL MEDICAL INC reported $256M of revenue over its last four quarters, through June 30, 2026.
Is SRTA profitable?
Yes. STRATA CRITICAL MEDICAL INC earned $40.2M over the last four quarters.
What is SRTA's EPS?
Diluted earnings per share over the last four quarters were $0.50; −$0.12 in the latest quarter.